** U.S.-listed shares of Oncolytics Biotech ONC.TO, ONCY.O rise 35.8% to $1.10 premarket
** ONCY says its pancreatic cancer therapy, pelareorep, has received regulatory approval to continue patient enrollment
** ONCY is evaluating pelareorep in combination with chemotherapy regimen Folfirinox and immunotherapy atezolizumab
** ONCY says it will move forward with full enrollment of 30 newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients in the first stage
** All 5 brokerages covering the stock rate it "buy"
** ONCY fell ~31% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。